TRPV6 and prostate carcinoma: Our studies were based on the fact that 1,25-dihydroxyvitamin D3, already used in the first stage of clinical trials was shown to be either unpredictable or inefficient in many cases, and the fact that TRPV6 which positively controls prostate cancer proliferation and apoptosis resistance [15] is a direct target of 1,25-dihydroxyvitamin D3 [17].